Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement MONROVIA, Calif., April 4, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.

Antibodies engineered with Xencor's proprietary Xtend&#8482 technology for increasing antibody half-life

Xencor Initiates Phase 1 Study of XmAb ® 5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response Monrovia, Calif. – Oct. 21, 2011 – Xencor, Inc., a company using its

Monrovia, Calif. – March 9, 2011 – Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (FcyRIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell

Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Thousand Oaks, Calif. and Monrovia, Calif. – (Jan. 6, 2011) – Amgen (NASDAQ: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered

Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia Monrovia, Calif. – December 2, 2010 – Xencor, Inc. and MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208),

Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Monrovia, CA—October 12, 2010 – Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program Martinsried/Munich, Germany, and Monrovia, Calif. – June 28, 2010 – MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) and US-based biopharmaceutical company Xencor, Inc., announced today the

Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer Monrovia, Calif. – February 9, 2010 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief

Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Monrovia, Calif. – January 19, 2010 – A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies

Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Monrovia, CA—December 16, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone

Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board Monrovia, CA—December 7, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Bruce Carter, Ph.D.

Xencor Licenses Antibody Optimization Technology Monrovia, Calif. – November 30, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology

Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board Monrovia, CA—June 29, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, today announced the addition of Jeffrey Ravetch,

Drug well tolerated with early signs of efficacy in heavily pretreated Hodgkin lymphoma patient population

First clinical data from a candidate developed using Xencor's antibody engineering platform

Xencor Licenses Xtend ™ Antibody Half-life Prolongation Platform to Merck & Co., Inc. Monrovia, CA – March 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a licensing transaction with Merck & Co., Inc.

Monrovia, CA – March 2, 2009. Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies.

Xencor and CSL Limited Establish Antibody Optimization Collaboration Monrovia, CA – February 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd.

Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology Monrovia, Calif. – December 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented results Sunday at the 50th

Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference Monrovia, Calif. – December 2, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485

Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO Monrovia, Calif. – June 1, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it will present new data from pre-clinical studies evaluating XmAb®5574, an Fc engineered monoclonal

Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR Monrovia, Calif. – April 15, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented data from its anti-CD19 antibody program during the Annual Meeting of the American Association for Cancer Research

Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings Monrovia, Calif. – April 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical CD19 program for lymphoma and leukemias at the Annual Meeting of the

Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors Monrovia, CA — March 19, 2008 — Xencor, Inc., a company developing protein and antibody therapeutics, today announced that it appointed David R. King as Chairman of its Board of Directors. To Xencor, Mr.